Germany · Delayed Price · Currency is EUR Hikma Pharmaceuticals Company Description
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market.
The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management.
It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally.
Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1978 |
| Industry | Pharmaceutical Preparations |
| Employees | 9,500 |
| CEO | Riad Mishlawi |
Contact Details
Address: 1 New Burlington Place London, W1S 2HR United Kingdom | |
| Phone | 44 20 7399 2760 |
| Website | hikma.com |
Stock Details
| Ticker Symbol | H5P |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riad Mishlawi | Chief Executive Officer |
| Khalid Walid Al Nabilsi | Chief Financial Officer |
| Guy Featherstone | Head of Investor Relations |